Update on Section 56 Exemption Application
929 Mainland Street
Vancouver, BC V6B 1S3
Phone
Fax
(604) 928-8913
(604) 628-0129
Email [email protected]
Website www.lexston.ca
NEWS RELEASE
LEXSTON LIFE SCIENCES CORP. HEALTH CANADA SECTION 56 EXEMPTION APPLICATION
Vancouver, British Columbia, July 13, 2021. Lexston Life Sciences Corp. (CSE: LEXT) (the “ Company” or
“Lexston”) is pleased to announce th at on July 9, 2021, the Company received an update from Health
Canada, that the application of its wholly owned subsidiary Egret Bioscience Ltd. ( “Egret”) submitted to
Health Canada for an exemption to use a controlled substance for scientific purposes, pursuant to Section
56(1) of the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (a " Section 56 Exemption") has been
screened and sent to the Office of Controlled Substances. Lexston will provide further update when more
information is received.
Lexston plans to develop and validat e methods for the detection and quantification of classical
psychedelics such as MDMA, DMT from multiple natural sources and psilocybin, indole alkaloids and
monoterpene indole alkaloids from Psilocybe mushrooms at their Kelowna research and development
laboratory utilizing their benchmark analytical instruments.
Additionally, in order to develop portable methods for the detection of these classical psychedelics,
Lexston, along with its collaborators at the University of Lausanne, Switzerland, plans to develop near
infrared spectroscopy (NIR) methods and associated chemometric models to enable the rapid
quantification of indole alkaloids and other classical psychedelics such as psilocybin and psilocin using the
MicroNIR Onsite W 1700 handheld device. This system has recently been used by law enforcement
agencies in over 60 jurisdictions in Switzerland and other European countries for the rapid and remote
detection of narcotics such as Heroin, Cocaine, MDM A, and Ketamine in less than 10 seconds
(https://www.sciencedirect.com/science/article/abs/pii/S0379073820303601).
“This is a key milestone for the Company, and we are excited at the prospects to leverage and expand on
our expertise in the chemical and genetic analyses of natural products to classical psychedelics. In
particular, our goal to democratize analytical workflows with the use of rapid and portable systems such
as the MicroNir holds promises to improve consistency, traceability and transparency and is expected to
benefit the psychedelic industry and the regulators alike.” Says Dr. Philippe Henry, Chief Science Officer
& Director of Lexston Life Sciences.
Egret has applied for an exemption under subsection 56(1) of the Controlled Drugs and Substances Act
(Canada) to use a controlled substance for scientific purposes under the protocol “ Establishing best
practices and analytical methods for the rapid detection, qu antification and traceability of botanically
Page | 2
derived classical psychedelics”. If granted, the exemption will allow Egret to purchase, possess and use a
specified quantity of the controlled substance for their research.
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. is a Canadian biotechnology company providing cannabis testing and research
services. Lexston is also in the process of securing licensing under the exemptions prescribed by section
56 of the Controlled Drugs and Substanc es Act (Canada) to enable the expansion of its services into the
psychedelic industry with an initial focus on the detection and quantification of psychedelic molecules in
the lab and point of care. Lexston intends to develop and validate methods for stand ardized
manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health
and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer
Telephone: (604) 928-8913
Forward Looking Information
This release includes forward -looking information within the meaning of Canadian securities laws
regarding Lexston and Egret and their respective businesses. Such statements are based on the current
expectations and views of future events of the management of each entity and are based on assumptions
and subject to risks and uncertainties. Although the management of each entity b elieves that the
assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward -
looking events and circumstances discussed in this release could differ materially as a result of known
and unknown risk factors and uncert ainties affecting the companies, including market conditions,
economic factors, management's ability to manage Lexston and Egret and the equity markets generally.
Although Lexston and Egret have attempted to identify important factors that could cause actual actions,
events or results to differ materially from those described in the forward-looking statements, there may
be other factors that cause actions, events or results to differ from those anticipated, estimated or
intended. Accordingly, readers should not place undue reliance on any forward -looking statements or
information. No forward -looking statement can be guaranteed. Except as required by applicable
securities laws, forward-looking statements speak only as of the date on which they are made and Lexston
and Egret do not undertake any obligation to publicly update or revise any forward looking statement,
whether as a result of new information, future events, or otherwise
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the
adequacy or accuracy of this release.